Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.
about
Biomarkers of Parkinson's disease: present and futureExpanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesFacilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich ImmunoassaysBiochemical Markers of Physical Exercise on Mild Cognitive Impairment and Dementia: Systematic Review and PerspectivesPreanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal VariationQuantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applicationsValue of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosisCerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker TeamThe influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathologyBrain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum diffEffect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau valuesAssociation of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer diseaseRecommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis.A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles.Heteromers of amyloid precursor protein in cerebrospinal fluid.The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease.Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progressionCerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.Alpha-synuclein levels in blood plasma decline with healthy aging.Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's diseaseA consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease.Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach.The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.Metabolic profiling of body fluids and multivariate data analysisCerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's DiseaseCSF biomarker variability in the Alzheimer's Association quality control program.Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy VolunteersAre CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical SettingConflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South KoreaDirect analytical sample quality assessment for biomarker investigation: qualifying cerebrospinal fluid samples.Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.How many biomarkers to discriminate neurodegenerative dementia?
P2860
Q24170134-4D690C40-43F0-44C7-9217-88353627DCEDQ26770708-864BF2F1-44E2-4BBE-A77E-897A8DC0C42EQ26781562-92C0B3C4-9430-463D-AA12-63E78E8B2C5EQ26784555-7CA91BDF-5698-4434-B820-78A34CC234B4Q26801663-DB0DC61C-8650-43B9-9E8A-7AE797563AA1Q26995267-8CE18458-3E82-4D4C-911C-987A5B006431Q28082380-9C081ADD-DF40-4D98-B359-B720CCC4F2B7Q28595520-15DFA336-9D28-453D-BBE8-9930C2FB351BQ29994562-12C99519-493C-4974-9235-E76875A0A951Q30416813-F83F3CDA-ED4D-451B-B9F1-17698D78A0EAQ33599653-2A2F5FAD-5312-414B-AAC7-C67C28AA3907Q33666297-92C967BE-776A-4034-9868-09DEF9D4FA17Q33740387-2F08D5E5-E8AE-41F6-9343-6369340BBE1AQ33771776-88052A24-3B03-4A25-BD2E-662DF8733AA9Q33800534-D5C23D33-38C2-4B3B-9FAC-C7DEC9FD279BQ33910641-70FBC654-31F1-48E4-9A31-93E7FCBA8BD2Q34630534-CE4790D3-21FD-4D4B-B4A7-A0E7237A4ECDQ34981218-557C9A6F-E333-482D-B99E-FEDB7F41E286Q35055373-4FC3EEFA-3413-432B-92AC-37DD9D76EF2DQ35106472-2F1C5674-F67D-4D98-B68E-0E3A9CD76302Q35117772-9B549C2E-D3B4-49FA-94A1-46B4C2B1F74CQ35284843-E4D93395-9497-41BD-A4C6-ACB803D43D0FQ35284971-63D61375-E18A-4D66-AD3C-E2D6A2577B3BQ35291150-FB5F69F3-490D-413E-9358-7F411E61431EQ35990600-831A7542-59F9-4886-B1BD-839FE3DDB65CQ36162523-439DCD86-5D72-4EC7-A860-E31D5C64F3B0Q36301588-86799B75-076B-4E1E-959B-F77F0586C053Q36322982-49C9EDA2-C8C4-44FC-AAFB-261D43C93EA8Q36999855-956C375E-812D-420E-91BA-D66383F9EAA2Q37053871-99115C5A-A5C9-4C65-828B-3E228D38ECF2Q37062574-5D59BEF4-0545-4ED8-8420-1CB6BDB87C3AQ37387826-8D23F258-3388-4259-98DB-D6EF88B36C12Q37487835-C8B7ABD1-B4A1-43A7-9E6B-0A94E30D88F5Q37665017-87F9C33D-F969-4285-B2C4-201D2160D240Q38232016-F637425E-57BD-4BD3-978C-D032CDED6B42Q38269095-E3FDCA89-7C63-4981-8427-E34B5B9C48ACQ38289739-5D2B5813-3F91-4B2C-877A-45781C479D07Q38299101-8AE2765D-48DC-4830-ADA5-93F6B9C476FFQ38384526-77EED82E-2187-400E-AEFA-2487D24E6162Q38570242-CAE531E6-E178-494A-AA03-EF12ACEF80C9
P2860
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recommendations to standardize ...... l fluid biomarkers: an update.
@en
type
label
Recommendations to standardize ...... l fluid biomarkers: an update.
@en
prefLabel
Recommendations to standardize ...... l fluid biomarkers: an update.
@en
P2093
P2860
P50
P921
P356
P1476
Recommendations to standardize ...... l fluid biomarkers: an update.
@en
P2093
Andrea Urbani
Armand Perret-Liaudet
Elisabeth Kapaki
Javier Sáez-Valero
Jose L Molinuevo
Lucilla Parnetti
Marcel Verbeek
Marta del Campo
Niels Kruse
P2860
P304
P356
10.2217/BMM.12.46
P50
P577
2012-08-01T00:00:00Z